Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE ZIDOVUDINE NEVIRAPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE ZIDOVUDINE NEVIRAPINE.
LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS vs LAMIVUDINE; ZIDOVUDINE; NEVIRAPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase by competing with natural substrates and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing conformational disruption. Zidovudine is an NRTI that inhibits viral reverse transcriptase after intracellular phosphorylation to its active triphosphate form.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 and HBV reverse transcriptase. Zidovudine is also an NRTI that inhibits HIV-1 reverse transcriptase. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds to HIV-1 reverse transcriptase and inhibits RNA-dependent and DNA-dependent DNA polymerase activities. The combination inhibits HIV replication.
One tablet (150 mg lamivudine/200 mg nevirapine/300 mg zidovudine) orally twice daily.
One tablet (150 mg lamivudine, 300 mg zidovudine, 200 mg nevirapine) orally twice daily.
None Documented
None Documented
Lamivudine: 5-7h (adults), prolonged in renal impairment. Nevirapine: 25-30h (single dose), 40-45h (multiple doses, autoinduction). Zidovudine: 0.5-3h (terminal), prolonged in hepatic impairment.
Lamivudine: 5-7 hours in adults, prolonged in renal impairment; Zidovudine: 0.5-3 hours, prolonged in hepatic impairment; Nevirapine: 25-30 hours (single dose), 40-45 hours after multiple doses due to autoinduction.
Lamivudine: ~70% renal (glomerular filtration and tubular secretion, unchanged). Nevirapine: ~80% biliary/fecal (metabolites), ~10% renal (unchanged). Zidovudine: ~75% renal (metabolism to glucuronide, tubular secretion).
Lamivudine: ~70% unchanged in urine via glomerular filtration and active tubular secretion; Zidovudine: ~75% metabolized to inactive glucuronide (G-ZDV), ~20% excreted unchanged in urine; Nevirapine: ~80% metabolized by CYP3A4/2B6, ~10% unchanged in urine, ~1% in feces.
Category A/B
Category A/B
NRTI
NRTI